Mark A Lewis1, Noura Sharabash1,2, Zhi-Feng Miao1,3, Lydia N Lyons1, Jay Piccirillo4, Donna Kallogjeri4, Mario Schootman1,5, Matthew Mutch6, Yan Yan7, Marc S Levin1,8, Antoni Castells9, Miriam Cuatrecasas9, Jason C Mills1,10,11, Zhen-Ning Wang3, Deborah C Rubin12,13. 1. Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, 660 South Euclid Avenue, Box 8124, St. Louis, MO, 63110, USA. 2. University of Illinois, Carle Clinics, 611 W. Park Street, Urbana, IL, 61801, USA. 3. Department of Surgical Oncology, First Hospital of China Medical University, No. 155 North Nanjing Street, Shenyang, Liaoning Province, China. 4. Department of Surgery, Washington University School of Medicine, 660 South Euclid Avenue, Box 8115, St. Louis, MO, 63110, USA. 5. St. Louis University School of Medicine, Salus Center, 3545 Lafayette Ave. Room 1401-K, St. Louis, MO, 63103, USA. 6. Department of Surgery, Washington University School of Medicine, 660 South Euclid Avenue, Box 8109, St. Louis, MO, 63110, USA. 7. Department of Surgery, Washington University School of Medicine, 660 South Euclid Avenue, Box 8100, St. Louis, MO, 63110, USA. 8. Veterans' Administration St. Louis Health Care System, St. Louis, MO, USA. 9. Hospital Clinic de Barcelona, Barcelona, Spain. 10. Department of Pathology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8124, St. Louis, MO, 63110, USA. 11. Department of Developmental Biology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8124, St. Louis, MO, 63110, USA. 12. Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, 660 South Euclid Avenue, Box 8124, St. Louis, MO, 63110, USA. drubin@wustl.edu. 13. Department of Developmental Biology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8124, St. Louis, MO, 63110, USA. drubin@wustl.edu.
Abstract
BACKGROUND: Colon cancer (CRC) is the third most common cancer worldwide. CRC develops through combinations of genetic and epigenetic changes. However, there is marked heterogeneity in the "driver gene" mutational profiles within and among colon cancers from individual patients, and these are not sufficient to explain differences in colon cancer behavior and treatment response. Global modulation of the tumor landscape may play a role in cancer behavior. Interferon-related developmental regulator 1 (IFRD1) is a transcriptional co-regulator that modulates expression of large gene cassettes and plays a role in gut epithelial proliferation following massive intestinal resection. AIMS: We address the hypothesis that increased IFRD1 expression in colon cancers is associated with poorer patient survival. METHODS: Tumor and normal tissue from colon cancer patient cohorts from the USA, Spain, and China were used for this study. Cancers were scored for the intensity of IFRD1 immunostaining. The primary clinical outcome was overall survival defined as time from diagnosis to death due to cancer. Kaplan-Meier method and log-rank analysis were used to assess the association between IFRD1 expression and survival. RESULTS: Almost all (98.7%) colon cancers showed readily detectable IFRD1 expression, with immunoreactivity primarily in the tumor cytoplasm. High IFRD1 colon cancer expression was significantly associated with decreased 5-year patient survival. Patients in the American cohort with high IFRD1 expression had a poorer prognosis. CONCLUSIONS: We have demonstrated that high IFRD1 protein expression in colon cancer is associated with poorer patient prognosis, suggesting a potential role for IFRD1 in modulating tumor behavior.
BACKGROUND:Colon cancer (CRC) is the third most common cancer worldwide. CRC develops through combinations of genetic and epigenetic changes. However, there is marked heterogeneity in the "driver gene" mutational profiles within and among colon cancers from individual patients, and these are not sufficient to explain differences in colon cancer behavior and treatment response. Global modulation of the tumor landscape may play a role in cancer behavior. Interferon-related developmental regulator 1 (IFRD1) is a transcriptional co-regulator that modulates expression of large gene cassettes and plays a role in gut epithelial proliferation following massive intestinal resection. AIMS: We address the hypothesis that increased IFRD1 expression in colon cancers is associated with poorer patient survival. METHODS:Tumor and normal tissue from colon cancerpatient cohorts from the USA, Spain, and China were used for this study. Cancers were scored for the intensity of IFRD1 immunostaining. The primary clinical outcome was overall survival defined as time from diagnosis to death due to cancer. Kaplan-Meier method and log-rank analysis were used to assess the association between IFRD1 expression and survival. RESULTS: Almost all (98.7%) colon cancers showed readily detectable IFRD1 expression, with immunoreactivity primarily in the tumor cytoplasm. High IFRD1colon cancer expression was significantly associated with decreased 5-year patient survival. Patients in the American cohort with high IFRD1 expression had a poorer prognosis. CONCLUSIONS: We have demonstrated that high IFRD1 protein expression in colon cancer is associated with poorer patient prognosis, suggesting a potential role for IFRD1 in modulating tumor behavior.
Entities:
Keywords:
Human colon cancer; IFRD1; Transcriptional co-regulator; Tumor landscape
Authors: Bing Zhang; Jing Wang; Xiaojing Wang; Jing Zhu; Qi Liu; Zhiao Shi; Matthew C Chambers; Lisa J Zimmerman; Kent F Shaddox; Sangtae Kim; Sherri R Davies; Sean Wang; Pei Wang; Christopher R Kinsinger; Robert C Rivers; Henry Rodriguez; R Reid Townsend; Matthew J C Ellis; Steven A Carr; David L Tabb; Robert J Coffey; Robbert J C Slebos; Daniel C Liebler Journal: Nature Date: 2014-07-20 Impact factor: 49.962
Authors: Mathias Uhlén; Erik Björling; Charlotta Agaton; Cristina Al-Khalili Szigyarto; Bahram Amini; Elisabet Andersen; Ann-Catrin Andersson; Pia Angelidou; Anna Asplund; Caroline Asplund; Lisa Berglund; Kristina Bergström; Harry Brumer; Dijana Cerjan; Marica Ekström; Adila Elobeid; Cecilia Eriksson; Linn Fagerberg; Ronny Falk; Jenny Fall; Mattias Forsberg; Marcus Gry Björklund; Kristoffer Gumbel; Asif Halimi; Inga Hallin; Carl Hamsten; Marianne Hansson; My Hedhammar; Görel Hercules; Caroline Kampf; Karin Larsson; Mats Lindskog; Wald Lodewyckx; Jan Lund; Joakim Lundeberg; Kristina Magnusson; Erik Malm; Peter Nilsson; Jenny Odling; Per Oksvold; Ingmarie Olsson; Emma Oster; Jenny Ottosson; Linda Paavilainen; Anja Persson; Rebecca Rimini; Johan Rockberg; Marcus Runeson; Asa Sivertsson; Anna Sköllermo; Johanna Steen; Maria Stenvall; Fredrik Sterky; Sara Strömberg; Mårten Sundberg; Hanna Tegel; Samuel Tourle; Eva Wahlund; Annelie Waldén; Jinghong Wan; Henrik Wernérus; Joakim Westberg; Kenneth Wester; Ulla Wrethagen; Lan Lan Xu; Sophia Hober; Fredrik Pontén Journal: Mol Cell Proteomics Date: 2005-08-27 Impact factor: 5.911
Authors: Jacob Sabates-Bellver; Laurens G Van der Flier; Mariagrazia de Palo; Elisa Cattaneo; Caroline Maake; Hubert Rehrauer; Endre Laczko; Michal A Kurowski; Janusz M Bujnicki; Mirco Menigatti; Judith Luz; Teresa V Ranalli; Vito Gomes; Alfredo Pastorelli; Roberto Faggiani; Marcello Anti; Josef Jiricny; Hans Clevers; Giancarlo Marra Journal: Mol Cancer Res Date: 2007-12 Impact factor: 5.852
Authors: YuanYuan Gu; Isaac T W Harley; Lindsay B Henderson; Bruce J Aronow; Ilja Vietor; Lukas A Huber; John B Harley; Jeffrey R Kilpatrick; Carl D Langefeld; Adrienne H Williams; Anil G Jegga; Jing Chen; Marsha Wills-Karp; S Hasan Arshad; Susan L Ewart; Chloe L Thio; Leah M Flick; Marie-Dominique Filippi; H Leighton Grimes; Mitchell L Drumm; Garry R Cutting; Michael R Knowles; Christopher L Karp Journal: Nature Date: 2009-02-25 Impact factor: 49.962
Authors: D Guardavaccaro; A Montagnoli; M T Ciotti; A Gatti; L Lotti; C Di Lazzaro; M R Torrisi; F Tirone Journal: J Neurosci Res Date: 1994-04-01 Impact factor: 4.164